Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CAH, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Chlorella | Diabetes | N/A · NCT01301287 | Unknown |
| 14-day Cerebrolysin treatment | Intracerebral Hemorrhage | Phase 4 · NCT06899464 | Not yet recruiting |
| Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg… | Galactose Single Point (GSP), Residual Liver Function | Phase 1/2 · NCT04546022 | Completed |
| Loxoprofen Pain Patch | Delayed Onset Muscle Soreness | Phase 2 · NCT02602353 | Completed |
| Technetium Tc 99m-labeled Tilmanocept | Anal Cancer | Phase 2 · NCT02857608 | Withdrawn |
| No Treatment | Delayed Onset Muscle Soreness | Phase 2 · NCT02602353 | Completed |
| Isosulfan Blue | Rhabdomyosarcoma | Phase 2 · NCT02509598 | Completed |
Also used in these trials (approved or third-party drugs, not CAH's own candidates): Simvastatin, Empagliflozin, Cisplatin, Nivolumab, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CAH holds $5.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAH files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 17,635,857 | 7.63% | 2026-03-31 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 13,786,683 | 5.96% | 2026-03-31 |
| Jason M. Hollar Chief Executive Officer |
Insider | 190,603 | 0.08% | 2026-08-18 |
| Deborah Weitzman CEO, PSS Segment |
Insider | 77,901 | 0.03% | 2026-08-18 |
| Gregory B Kenny Director |
Insider | 64,194 | 0.03% | 2025-11-05 |
| Jessica L Mayer Chief Legal/Compliance Officer |
Insider | 33,076 | 0.01% | 2026-08-18 |
| Patricia Hemingway Hall Director |
Insider | 29,849 | 0.01% | 2026-11-12 |
| Nancy Killefer Director |
Insider | 28,379 | 0.01% | 2026-11-12 |
| Akhil Johri Director |
Insider | 22,869 | 0.01% | 2026-11-12 |
| Aaron E Alt Chief Financial Officer |
Insider | 20,495 | 0.01% | 2026-08-18 |
| Stephen M Mason CEO, GMPD Segment |
Insider | 18,061 | 0.01% | 2026-08-18 |
| David C Evans Director |
Insider | 16,128 | 0.01% | 2026-11-12 |
Share count 231,136,655 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAH and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →